Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDC-G305 · 1 trial · 5 indications
To evaluate the safety and tolerability of multiple ascending doses of intramuscular (IM) IDC-G305
| Arm | Type | Description |
|---|---|---|
| IDC-G305 | EXPERIMENTAL | NY-ESO-1 recombinant protein together with GLA-SE |
| Name | Type | Description |
|---|---|---|
| IDC-G305 | BIOLOGICAL | NY-ESO-1 recombinant protein together with GLA-SE |
Inclusion Criteria: * Confirmed diagnosis of melanoma, ovarian cancer, sarcoma, breast cancer or non-small cell lung cancer (NSCLC) * Unresectable, relapsed and/or metastatic cancer with minimal or low disease burden. Disease may or may not be measurable and should not be rapidly progressive. Inade...
Top 20 of 51 competitors
IDC-G305 is an investigational monoclonal antibody being developed for the treatment of melanoma. It is currently in Phase 1 clinical development. The drug is being studied in patients with unresectable or metastatic cancer, including melanoma, as part of an early-stage clinical trial.
IDC-G305 is being developed by Design Therapeutics, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol DSGN. The drug is currently in Phase 1 clinical development for the treatment of melanoma.
IDC-G305 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied in an early-stage clinical trial to evaluate its safety and potential efficacy in patients with melanoma.
IDC-G305 is associated with clinical trial NCT02015416, titled 'A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer'. This trial has been completed and enrolled 13 participants with conditions including melanoma, ovarian cancer, sarcoma, non-small cell lung cancer, and breast cancer.
IDC-G305 is not the same as NY-ESO-1. The clinical trial NCT02015416 involves NY-ESO-1 with GLA-SE, which is a different investigational therapy. IDC-G305 is a separate monoclonal antibody being developed by Design Therapeutics for melanoma, and it is not listed as an alternative name for NY-ESO-1.